Paper Details

  1. Home
  2. Paper Details

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.

Author: AyusoC, BianchiL, BruixJ, CastellsL, LlovetJ M, RodésJ, SalaM, SuarezY, VargasV, VilanaR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized controlled trial evaluated the efficacy of interferon alfa-2b (IFN) in the treatment of advanced hepatocellular carcinoma (HCC). The study found that IFN was not well tolerated and did not improve survival or tumor progression rates in patients with cirrhosis and advanced HCC.
Paper Details　
Original Abstract of the Article :
The aim of this randomized controlled trial was to assess the efficacy of interferon alfa-2b (IFN) for the treatment of advanced hepatocellular carcinoma (HCC). Fifty-eight patients with HCC who were not suitable for resection, transplantation, ethanol injection, or arterial embolization were strati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/hep.510310111

データ提供：米国国立医学図書館（NLM）

Interferon Treatment for Advanced Hepatocellular Carcinoma: A Desert of Challenges

Hepatocellular carcinoma (HCC), a formidable foe, can feel like a relentless sandstorm, relentlessly eroding health. This randomized controlled trial investigates the efficacy of interferon alfa-2b (IFN) for treating advanced HCC, seeking to determine if this therapy can offer a lifeline in the face of this challenging disease.

Navigating the Complexities of HCC Treatment

The study, like a daring desert expedition, evaluates the impact of IFN on survival and tumor progression in patients with advanced HCC. The researchers meticulously analyze the data, comparing IFN to symptomatic treatment, to understand its potential benefits and limitations.

A Balancing Act in HCC Treatment

The study's findings highlight the complexities of treating advanced HCC. While IFN showed some promise in terms of partial response, it was also associated with significant side effects, making its overall impact on survival and quality of life uncertain.

Dr.Camel's Conclusion

This research, like a desert journey marked by both hope and hardship, underscores the need for ongoing investigation into more effective therapies for HCC. The challenges presented in this study highlight the importance of understanding the complexities of the disease and exploring new avenues for treatment.
Date :
  1. Date Completed 2000-01-13
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

10613728

DOI: Digital Object Identifier

10.1002/hep.510310111

Related Literature

Article Analysis
・Side Effects of interferon alfa-2b injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.